deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT02420652

Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy (PRIMA)

A Phase 2 Randomized Discontinuation Trial in Patients With Hormone-Dependent Rising Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer Evaluating the Synergy of Metformin Plus Aspirin (PRIMA Trial)

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Prostate Carcinoma Stage I Prostate Cancer Stage IIA Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer
Interventions Aspirin Laboratory Biomarker Analysis Metformin Hydrochloride Placebo
Updated 14 times since 2017 Last updated: Feb 6, 2023 Started: Jun 23, 2015 Primary completion: Dec 1, 2019 Completion: Dec 1, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

This PHASE2 trial investigates Recurrent Prostate Carcinoma and Stage I Prostate Cancer and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Mar 2018 · 5 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jun 2019 · 9 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Jul 2020 · 12 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2023 · 26 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Mar 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Mar 2023 [monthly]

    Terminated PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 9 earlier versions

  1. Jul 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Oct 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  8. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Rutgers Cancer Institute of New Jersey
  • Rutgers, The State University of New Jersey
Data source: Rutgers, The State University of New Jersey

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations